恩扎卢胺联合ADT对mHSPC患者健康相关生活质量的影响:ARCHES随机对照3期研究分析
ARCHES研究纳入1150例mHSPC患者,随机接受恩扎卢胺(160 mg/日)联合ADT或安慰剂联合ADT。至第73周,两组总体HRQoL和疼痛均维持良好,恩扎卢胺在部分HRQoL子量表和疼痛严重程度上延迟了恶化,但多数差异未达统计学显著。
要点
- 恩扎卢胺联合ADT使mHSPC患者维持高功能HRQoL和低症状负担。
- 恩扎卢胺显著延迟最严重疼痛(约3个月)和疼痛严重程度的首次临床意义恶化。
- QLQ-PR25和FACT-P评分在首次和首次确认恶化上均无显著组间差异。
核心结论
- 恩扎卢胺联合ADT使mHSPC患者能够维持高功能HRQoL和低症状负担。
研究设计与样本
- ARCHES(NCT02677896)为随机、双盲、安慰剂对照3期研究,纳入mHSPC患者。
- 共1150例患者接受ADT联合恩扎卢胺(n=574)或安慰剂(n=576)。
- PROs在基线、第13周及每12周直至疾病进展时评估。
主要发现
- 基线PRO评分显示高HRQoL和低疼痛,两组 generally 维持。
- QLQ-PR25和FACT-P评分在TTFD和TTFCD上均无统计学显著组间差异(nominal p>0.05)。
- 恩扎卢胺显著延迟最严重疼痛TTFD约3个月(nominal p=0.032)。
- 恩扎卢胺显著延迟疼痛严重程度TTFD(nominal p=0.021)。
- 恩扎卢胺显著延迟EQ-5D-5L视觉模拟评分TTFD(nominal p=0.0070)。
关键数值与推荐
- 恩扎卢胺剂量为160 mg/日。
- PRO评估工具包括QLQ-PR25、FACT-P、BPI-SF和EQ-5D-5L。
- 疼痛结局的确认恶化无统计学显著性。
临床怎么用
- 对于mHSPC患者,恩扎卢胺联合ADT在改善影像学无进展生存的同时不损害HRQoL。
- 恩扎卢胺可能有助于延迟疼痛恶化,尤其在高瘤负荷患者中。
局限性
- 疼痛结局的确认恶化无统计学显著性。
- HRQoL子量表恶化的延迟仅在部分指标中观察到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the ARCHES study in metastatic hormone-sensitive prostate cancer (mHSPC), enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) versus ADT alone. OBJECTIVE: To evaluate patient-reported outcomes (PROs) to week 73. DESIGN, SETTING, AND PARTICIPANTS: ARCHES (NCT02677896) was a randomised, double-blind, placebo-controlled, phase 3 study in mHSPC patients. INTERVENTION: Enzalutamide (160 mg/day) plus ADT or placebo plus ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PROs were assessed at baseline, week 13, and every 12 wk until disease progression using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate 25 (QLQ-PR25), Functional Assessment of Cancer Therapy-Prostate (FACT-P), Brief Pain Inventory Short Form, and EuroQoL 5-Dimensions, 5-Levels (EQ-5D-5 L) instruments. Endpoints included time to first (TTFD) and first confirmed (TTFCD) clinically meaningful deterioration (using predefined questionnaire thresholds) in health-related quality of life (HRQoL) and pain. RESULTS AND LIMITATIONS: A total of 1150 patients received ADT plus enzalutamide (n = 574) or placebo (n = 576). Baseline PRO scores indicated high HRQoL and low pain, which was generally maintained in both groups. There were no statistically significant (nominal p > 0.05) between-group differences that occurred in both TTFD and TTFCD together for QLQ-PR25 and FACT-P scores. Enzalutamide significantly delayed TTFD in worst pain (by ∼3 mo; nominal p = 0.032), pain severity (nominal p = 0.021), and EQ-5D-5 L visual analogue scale score (nominal p = 0.0070) versus placebo (not significant for confirmed deterioration for pain outcomes). Enzalutamide delays deterioration in several HRQoL subscales and pain severity in high-volume disease. CONCLUSIONS: Enzalutamide plus ADT enables men with mHSPC to maintain high-functioning HRQoL and low symptom burden. PATIENT SUMMARY: This study examined the effect on health-related quality of life and pain of adding enzalutamide or placebo to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer. Addition of enzalutamide allowed patients to maintain their health-related quality of life.
引用
- Stenzl A, Dunshee C, De Giorgi U, et al. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020. PMID: 32336645. doi:10.1016/j.eururo.2020.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。